Translation Control Therapeutics
Lighting up a novel target space
mRNA translation

AnimaBiotech

Translation Control Therapeutics, a novel approach for the discovery of small molecules that selectively control mRNA translation as a new strategy against hard targets and undruggable proteins

Watch Movie: mRNA translation control

Small molecule drugs targeting novel proteins involved in the regulation of mRNA translation

The Selectivity of Translation Biology

Tissue
Tissue specific regulation
Cells
Normal vs. cancer cells
Pathway
Up or down regulated in pathological pathway
mRNA
Sequence and structure

Our Approach

Cells control protein translation using multiple selective mechanisms, offering novel intervention points. Modulation of translation is therefore possible with highly selective drugs.

mRNA translation modulators
A novel target space

mRNA
Biology
Ribosome accessory proteins
Epitranscriptomics (mRNA modifying proteins)
Splicing factors
Modifiers of ribosomal proteins (Kinases, methylases etc...)
tRNA abundance and control
RNA binding proteins

Selective translation modulators with novel mechanisms of action elucidated by Anima’s proprietary technologies

Translation Control Therapeutics platform

Watch Movie: Translation Control Therapeutics Platform

Our proprietary platform controls mRNA Translation Biology

See the Light of Protein Translation

Anima’s science is using fluorescently labeled tRNA pairs to generate FRET signals, light pulses emitted from the ribosomes to visualize the translation of any protein of interest and identify selective translation modulators

mRNA Translation Modulators Pipeline

Our pipeline programs are in Fibrosis (Collagen type I translation inhibitors), Oncology (c-Myc translation inhibitors and K-Ras translation inhibitors), Neuroscience (mHTT translation inhibitors, expanded to a broader strategy against Repeat Associated Diseases) and Infectious diseases (RSV viral proteins translation inhibitors)

Program
DISCOVERY
OPTIMIZATION
IND ENABLING
Fibrosis
Oncology
K-Ras
Neuroscience
lilly logo | targets
Infectious diseases

Pharma Collaborations

Anima Biotech announces a strategic collaboration with Lilly for the discovery and development of translation inhibitors of several protein targets

$30 million in upfront payments, $14 million in research funding, up to $1.05 billion in milestones and low to mid single-digit tiered royalties on sales of any Lilly products resulting from the collaboration.

For partnering inquiries, please contact [email protected].

17 Scientific Collaborations

15 Publications

Coverage

News & Events

  • 3rd Annual RNA-Targeted Drug Discovery Conference

    When: Dec. 8th, 2020 - Dec. 10th, 2020

    Anima Biotech has been invited to present and participate in multiple sessions during the 3rd Annual RNA-Targeted Drug Discovery Conference, between Dec. 8-10, 2020. Yochi Slonim, Co-founder and CEO of Anima Biotech, will be giving a presentation, titled, “Translation Control Therapeutics: Discovery of Selective mRNA Translation Modulators,” and will also serve on an expert panel, titled, “From Theory to Reality: How to Target RNA Biology with Small Molecule Approaches.” Iris Alroy, VP of R&D, will also participate in an expert Q&A session.

    Download Press Release »

    Visit the conference website »

  • 2nd Annual RNA as a Drug Target Conference

    When: Sep. 16th, 2020 - Sep. 18th, 2020

    Anima Biotech has been invited to present and participate on an expert panel during the Cambridge Healthtech Institute’s 2nd Annual RNA as a Drug Target Conference, between Sep. 16-17, 2020. Yochi Slonim, Co-founder and CEO of Anima Biotech, will be giving a presentation during the RNA as a Drug Target session, titled, “Translation Control Therapeutics: Discovery of Selective mRNA Translation Modulators, on Thursday, Sep. 17 at 10:15 a.m. ET. As part of the same session, Dr. Iris Alroy, VP of R&D, will participate on an expert wrap-up panel discussion on Thursday, Sep. 17 at 11:35 a.m. ET.

    Download Press Release »

    Visit the conference website »

  • Cambridge Healthtech Institute’s Inaugural RNA as a Small Molecule Target Symposium

    When: Aug. 28th, 2020

    Anima Biotech has been invited to give an overview of its Translation Control Therapeutics platform at the Inaugural RNA as a Small Molecule Target Symposium. Co-founder and CEO, Yochi Slonim and vice president of research and development Dr. Iris Alroy will jointly present a talk titled “Translation Control Therapeutics: Discovery of Selective mRNA Translation Modulators,” on Friday, Aug.

    Download Press Release »

    Visit the conference website »